2010•Cancer Treatment ReviewsOpen access

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Sérgio Rizzo, Giuseppe Bronte, Daniele Fanale, Lidia Rita Corsini, Nicola Silvestris, Daniele Santini, Gaspare Gulotta, Viviana Bazan, Nicola Gebbia, Fabio Fulfaro, Antonio Russo

Open full text 106 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 106 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Panitumumab, Cetuximab, KRAS, Medicine, Epidermal growth factor receptor, Colorectal cancer, Predictive marker, EGFR inhibitors

Back to paper search Browse research topics Original source

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? — Research Paper | ScholarLens